How mRNA therapeutics are entering the monoclonal antibody field

Journal of Translational Medicine
Lien Van Hoecke, Kenny Roose

Abstract

In 1975, Milstein and Köhler revolutionized the medical world with the development of the hybridoma technique to produce monoclonal antibodies. Since then, monoclonal antibodies have entered almost every branch of biomedical research. Antibodies are now used as frontline therapeutics in highly divergent indications, ranging from autoimmune disease over allergic asthma to cancer. Wider accessibility and implementation of antibody-based therapeutics is however hindered by manufacturing challenges and high development costs inherent to protein-based drugs. For these reasons, alternative ways are being pursued to produce and deliver antibodies more cost-effectively without hampering safety. Over the past decade, messenger RNA (mRNA) based drugs have emerged as a highly appealing new class of biologics that can be used to encode any protein of interest directly in vivo. Whereas current clinical efforts to use mRNA as a drug are mainly situated at the level of prophylactic and therapeutic vaccination, three recent preclinical studies have addressed the feasibility of using mRNA to encode therapeutic antibodies directly in vivo. Here, we highlight the potential of mRNA-based approaches to solve several of the issues associated with an...Continue Reading

References

Nov 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·G J Cao, N Sarkar
Mar 23, 1990·Science·J A WolffP L Felgner
Nov 11, 1987·Nucleic Acids Research·J F MilliganO C Uhlenbeck
Dec 1, 1994·Vaccine·I Danko, J A Wolff
Jun 1, 1997·Vaccine·M A LiuJ Donnelly
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·R TeitelbaumB R Bloom
Mar 26, 2003·European Journal of Biochemistry·Genoveva A Nacheva, Alfredo Berzal-Herranz
Oct 17, 2003·The Journal of Clinical Investigation·Joshua D NosanchukArturo Casadevall
Jan 30, 2004·Nature Structural & Molecular Biology·Roy Parker, Haiwei Song
Feb 21, 2004·Science·Sandra S DieboldCaetano Reis e Sousa
Jul 23, 2004·Expert Opinion on Biological Therapy·Steve Pascolo
Oct 8, 2005·Nature Biotechnology·H Kaspar BinzAndreas Plückthun
Oct 3, 2006·European Journal of Immunology·Birgit ScheelSteve Pascolo
Oct 14, 2006·Science·Andreas PichlmairCaetano Reis e Sousa
Jul 24, 2007·Current Opinion in Biotechnology·Arne Skerra
Dec 12, 2007·Handbook of Experimental Pharmacology·Steve Pascolo
Dec 12, 2007·Handbook of Experimental Pharmacology·A Nissim, Y Chernajovsky
May 27, 2008·Nature Biotechnology·Yannick DoyonSharon L Amacher
Sep 18, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Katalin KarikóDrew Weissman
May 23, 2009·British Journal of Pharmacology·Patrick ChamesDaniel Baty
May 12, 2010·Nucleic Acids Research·Bart R AndersonKatalin Karikó
Jul 9, 2010·Clinical Pharmacokinetics·Ron J KeizerJos H Beijnen
Jan 11, 2011·Nature Biotechnology·Michael S D KormannCarsten Rudolph

❮ Previous
Next ❯

Citations

Feb 26, 2020·Nanomaterials·Itziar Gómez-AguadoAna Del Pozo-Rodríguez
Feb 6, 2020·Pharmaceutics·Abishek WadhwaAneesh Thakur
May 31, 2020·International Journal of Molecular Sciences·Hagma H WorkelMarco de Bruyn
Oct 8, 2020·Drug Delivery and Translational Research·Marianne Ashford
Jan 23, 2021·Vaccines·Michael D BuschmannDrew Weissman
Feb 13, 2021·Vaccines·Cailin E DealObadiah J Plante
Jan 23, 2021·Cells·Palas K ChandaJohn P Cooke
Nov 17, 2020·Frontiers in Chemistry·Maria L GuevaraStefano Persano
Oct 12, 2020·Advanced Drug Delivery Reviews·Qiangbing YangRaymond Schiffelers
Jul 23, 2020·Molecular Therapy. Methods & Clinical Development·Jesse H ErasmusNeal Van Hoeven
Mar 7, 2021·International Journal of Molecular Sciences·Jilly Frances EvansVera P Krymskaya
Jun 5, 2019·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yulia RybakovaDaniel G Anderson
Mar 12, 2021·BMC Biotechnology·Cynthia AslanReza Jafari
Apr 3, 2021·Nature Biomedical Engineering·Ava M VargasonSamir Mitragotri
Dec 6, 2020·Seminars in Immunology·Simone PecettaAnja Seubert
Jun 3, 2021·Pharmaceutics·Julen Rodríguez-CastejónAlicia Rodríguez-Gascón
Jul 15, 2021·Human Vaccines & Immunotherapeutics·Kevin J Whaley, Larry Zeitlin
Apr 18, 2021·Annual Review of Biomedical Engineering·Neha N Parayath, Matthias T Stephan
Jul 16, 2021·Molecular Pharmaceutics·Despo ChatzikleanthousRoberto Adamo
Jul 31, 2021·Wiley Interdisciplinary Reviews. RNA·Manuel D Diaz-Muñoz, Ines C Osma-Garcia
Aug 2, 2021·Molecular Aspects of Medicine·Manish PandeyGeetanjali Chawla
Aug 18, 2021·Pharmacology & Therapeutics·Ai-Ming Yu, Mei-Juan Tu
Aug 27, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·N N ParayathM T Stephan
Oct 28, 2021·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Andrea L J Marschall
Dec 24, 2021·DNA and Cell Biology·Joshua Tan

❮ Previous
Next ❯

Methods Mentioned

BETA
in vitro transcription
transfection
xenografts
chemical modification
MDA

Clinical Trials Mentioned

NCT03076385

Software Mentioned

BiTE

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Keiji Itaka
Nihon rinsho. Japanese journal of clinical medicine
Kei Ohnuma, Chikao Morimoto
© 2022 Meta ULC. All rights reserved